Cargando…
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity, and reproducibility of ctDNA assays is poorly understood. Here we report the findings of a multi-site, cross-platform evaluation of the analytical performance of five industry-lead...
Ejemplares similares
-
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
por: Willey, James C., et al.
Publicado: (2021) -
ELXR: a resource for rapid exon-directed sequence analysis
por: Schageman, Jeoffrey J, et al.
Publicado: (2004) -
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
por: Gong, Binsheng, et al.
Publicado: (2021) -
Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing
por: Lee, Chul Seung, et al.
Publicado: (2021) -
The Complete Exosome Workflow Solution: From Isolation to Characterization of RNA Cargo
por: Schageman, Jeoffrey, et al.
Publicado: (2013)